815 material Form 8-K filings that 659 companies we cover made with the SEC in March 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Eledon Pharmaceuticals reported its fourth quarter and full year 2025 results on March 19, 2026. The net loss for 2025 widened to $45.6 million from $36.2 million, driven by higher research and development expenses, though the loss per share narrowed to $0.52 from $0.66 on a larger share count.
Full-year 2025 net loss was $45.6 million, or $0.52 per basic share, versus $36.2 million, or $0.66 per share, in 2024.
Research and development expenses rose to $66.3 million from $52.0 million, which the company attributed to clinical trial activity, manufacturing scale-up and added personnel.
A non-cash gain of $33.4 million from changes in the fair value of warrant liabilities reduced the 2025 net loss; excluding warrant items, the net loss would have been $79.1 million.
GrowGeneration reported fourth-quarter and full-year 2025 results, with full-year net sales down to $161.7 million from $188.9 million after store closures, while the GAAP net loss narrowed to $24.0 million from $49.5 million. The company also gave 2026 guidance of $162 million to $168 million in revenue and breakeven Adjusted EBITDA, and its board authorized a share repurchase of up to $10 million of common stock.
Full-year 2025 net sales were $161.7 million, down from $188.9 million in 2024, reflecting retail store consolidations.
Full-year 2025 GAAP net loss was $24.0 million versus $49.5 million in 2024; Adjusted EBITDA loss was $6.0 million versus $14.5 million.
Board authorized repurchases of up to $10 million of common stock, which may begin after customary administrative and regulatory processes and may run for up to two years.
2026 outlook calls for revenue of $162 million to $168 million, gross margin of 27% to 29%, and breakeven Adjusted EBITDA for the full year.
Scholastic reported fiscal third-quarter revenue of $329.1 million, down 2% from a year earlier, and an operating loss of $26.9 million compared with $23.9 million a year ago. Diluted earnings per share rose to $2.55 from a loss of $0.13, driven by a $119.8 million pretax gain on sale-leaseback transactions, and the company reaffirmed its full-year Adjusted EBITDA outlook of $146 million to $156 million. The board also authorized a $300 million share repurchase program, including a planned $200 million tender offer priced between $36 and $40 per share.
Revenue was $329.1 million, down 2% from $335.4 million; Adjusted EBITDA was $0.0 million versus $6.0 million a year earlier.
Operating loss was $26.9 million versus $23.9 million; net income of $62.5 million includes a $119.8 million pretax gain on sale-leaseback transactions.
Full-year Adjusted EBITDA outlook of $146 million to $156 million was reaffirmed, and full-year revenue is expected to be approximately flat.
A $200 million modified Dutch auction tender offer, priced at $36 to $40 per share, is anticipated to launch in the coming days.
ACCESS Newswire reported fourth-quarter and full-year 2025 results, with full-year revenue down 2% to $22.6 million from $23.1 million in 2024. The loss from continuing operations narrowed sharply to $1.6 million from $13.3 million, mainly because 2024 included a $14.15 million impairment charge, and adjusted EBITDA rose to $3.2 million from $1.8 million.
Q4 2025 revenue was $5.8 million, flat versus Q4 2024 and up 1% from $5.7 million in Q3 2025.
Full-year 2025 revenue was $22.6 million, down 2% from $23.1 million in 2024, driven by lower PRO plan and webcasting and events revenue.
Q4 2025 net loss from continuing operations was $0.5 million, or $0.13 per diluted share, versus $10.9 million, or $2.85 per share, in Q4 2024.
Full-year 2025 net income was $4.3 million including discontinued operations, which included a $9.0 million gain on disposal of a business.
Titan Machinery reported fourth-quarter fiscal 2026 revenue of $641.8 million, down from $759.9 million a year earlier, while its net loss narrowed to $36.2 million from $43.8 million. For the full fiscal year, revenue fell to $2.4 billion from $2.7 billion and the net loss widened to $54.2 million, or $2.38 per diluted share, from $36.9 million, or $1.63 per share. The company also introduced fiscal 2027 modeling assumptions that point to a further decline in revenue in its Agriculture segment and a continued loss, which shareholders will weigh against the fiscal 2026 results.
Q4 fiscal 2026 net loss was $36.2 million, or $1.59 per diluted share, versus $43.8 million, or $1.93 per share, a year earlier; gross margin rose to 13.5% from 6.7%.
Full-year fiscal 2026 adjusted EBITDA was $13.9 million, up from $12.8 million in fiscal 2025, while reported net loss was $54.2 million.
Inventory fell $206 million in fiscal 2026, above the $150 million target, and the company says it has no further targeted inventory reductions planned for fiscal 2027.
Fiscal 2027 assumptions include adjusted EBITDA of $17.0 million to $29.0 million and adjusted diluted loss per share of $1.25 to $1.75, compared with an adjusted loss of $2.22 per share in fiscal 2026.
SOLV Energy reported fourth-quarter and full-year 2025 results, with full-year revenue of $2.49 billion versus $1.85 billion a year earlier and net income of $149 million versus $10 million. The company also initiated 2026 guidance calling for revenue of $3.72 billion to $3.82 billion and adjusted EBITDA of $400 million to $420 million, which gives shareholders a first forward view of the business after its IPO.
Q4 2025 revenue was $794 million versus $441 million in Q4 2024; Q4 gross margin was 18.1% versus 18.5%.
Full-year 2025 adjusted EBITDA was $342 million versus $165 million in 2024.
2026 guidance: revenue of $3.72 billion to $3.82 billion, gross profit of $580 million to $620 million, adjusted EBITDA of $400 million to $420 million.
Year-end 2025 backlog was $8 billion, up 87% from year-end 2024; the IPO raised $552.5 million in net proceeds.
Darden reported fiscal third-quarter 2026 sales of $3.3 billion, up 5.9%, with same-restaurant sales up 4.2%. Reported diluted EPS from continuing operations fell to $2.68 from $2.74, while adjusted EPS rose 5.4% to $2.95 after excluding impairment and strategic review costs. The company also updated its fiscal 2026 adjusted EPS outlook to $10.57 to $10.67 and declared a $1.50 quarterly dividend.
Q3 total sales rose 5.9% to $3.3 billion; same-restaurant sales rose 4.2%, with LongHorn Steakhouse up 7.2% and Olive Garden up 3.2%.
Reported diluted EPS from continuing operations was $2.68, down from $2.74; adjusted EPS was $2.95, up 5.4%, excluding $0.16 of restaurant closure impairment.
Fiscal 2026 adjusted EPS outlook is $10.57 to $10.67, including about $0.25 from a 53rd week.
Darden repurchased $127 million of stock in the quarter, with $516 million left under a $1 billion authorization; quarterly dividend of $1.50 per share is payable May 1, 2026.
Signet reported fourth-quarter sales of $2.35 billion and adjusted diluted EPS of $6.25, down from $6.62 a year earlier, while full-year adjusted diluted EPS rose to $9.60 from $8.94. The company introduced fiscal 2027 guidance calling for total sales of $6.6 billion to $6.9 billion and adjusted diluted EPS of $8.80 to $10.74, and raised its quarterly dividend to $0.35 per share. Shareholders get a dividend increase and a outlook, but the fourth-quarter adjusted profit decline and the planned James Allen transition, which the company says will cost $60 million to $80 million in net revenue, are factors to weigh.
Q4 sales of $2.35 billion, same store sales down 0.7%; adjusted diluted EPS $6.25 vs. $6.62 in Q4 of FY25
Full-year GAAP diluted EPS of $7.08 vs. a loss of $0.81 in FY25; adjusted diluted EPS $9.60 vs. $8.94
FY27 guidance: total sales $6.6 to $6.9 billion; adjusted diluted EPS $8.80 to $10.74
Quarterly dividend raised to $0.35 per share, payable May 22, 2026, to holders of record April 24, 2026
Accenture reported second-quarter fiscal 2026 revenue of $18.0 billion, up 8% in U.S. dollars and 4% in local currency, and diluted earnings per share of $2.93, up 4% from $2.82 a year earlier. The company raised its full-year free cash flow outlook to $10.8 billion to $11.5 billion and raised the low end of its revenue growth and GAAP earnings per share ranges, which matters to shareholders because it points to higher expected cash generation and profit.
Revenue of $18.04 billion, up 8% in U.S. dollars and 4% in local currency; new bookings of $22.11 billion, up 6% in U.S. dollars.
Diluted EPS of $2.93 versus $2.82 a year earlier; operating margin of 13.8% versus 13.5%.
Full-year fiscal 2026 local-currency revenue growth now expected at 3% to 5%, up from 2% to 5%; free cash flow now $10.8 billion to $11.5 billion, up from $9.8 billion to $10.5 billion.
Quarterly dividend of $1.63 per share, up 10%, payable May 15, 2026; $1.7 billion spent on share repurchases in the quarter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.